Search research articles
Contact Us
Filters
Showing results (131-140 of 862) with videos related to
Page
of 87
Sort By:
Plos One
|
June 2, 2012
Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by ifenprodil: the role of sigma-1 and IP3 receptors
Tamaki Ishima, Kenji Hashimoto
Annals of General Psychiatry
|
December 23, 2009
Fluvoxamine monotherapy for psychotic depression: the potential role of sigma-1 receptors
Tsutomu Furuse, Kenji Hashimoto
Human Psychopharmacology
|
April 8, 2010
Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered
Ian Hindmarch, Kenji Hashimoto
The Primary Care Companion for CNS Disorders
|
April 16, 2013
Beneficial effects of the sigma-1 agonist fluvoxamine for tardive dyskinesia in patients with postpsychotic depressive disorder of schizophrenia: report of 5 cases
Yakup Albayrak, Kenji Hashimoto
The Australian and New Zealand Journal of Psychiatry
|
October 5, 2014
Old drug tipepidine as new hope for children with ADHD
Kenji Hashimoto, Tsuyoshi Sasaki
Nihon Arukoru Yakubutsu Igakkai Zasshi = Japanese Journal of Alcohol Studies & Drug Dependence
|
June 4, 2008
[Progress in diagnosis of psychiatric diseases using blood samples--recent findings of brain-periphery interaction in drug abusers]
Hiroko Hagiwara, Kenji Hashimoto
Annals of General Psychiatry
|
February 12, 2010
Sigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer's disease
Tsutomu Furuse, Kenji Hashimoto
Proceedings of the National Academy of Sciences of the United States of America
|
January 14, 2021
Reply to Reeves and Dunn: Risk for autism in offspring after maternal glyphosate exposure
Kenji Hashimoto, Bruce D Hammock
Journal of Clinical Psychopharmacology
|
September 2, 2011
Effects of add-on cilostazol on cognition in patients with schizophrenia: an open-label pilot trial
Yukihiko Shirayama, Takeshi Konishi, Kenji Hashimoto
Molecular Psychiatry
|
April 7, 2022
Comments to "Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists" by Khani and Entezari-Maleki
Yaeko Hashimoto, Takuji Suzuki, Kenji Hashimoto
Page
of 87
Search research articles
Search
Showing results (131-140 of 862) with videos related to
Sort By:
Page
of 87
Plos One
|
June 2, 2012
Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by ifenprodil: the role of sigma-1 and IP3 receptors
Tamaki Ishima, Kenji Hashimoto
Annals of General Psychiatry
|
December 23, 2009
Fluvoxamine monotherapy for psychotic depression: the potential role of sigma-1 receptors
Tsutomu Furuse, Kenji Hashimoto
Human Psychopharmacology
|
April 8, 2010
Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered
Ian Hindmarch, Kenji Hashimoto
The Primary Care Companion for CNS Disorders
|
April 16, 2013
Beneficial effects of the sigma-1 agonist fluvoxamine for tardive dyskinesia in patients with postpsychotic depressive disorder of schizophrenia: report of 5 cases
Yakup Albayrak, Kenji Hashimoto
The Australian and New Zealand Journal of Psychiatry
|
October 5, 2014
Old drug tipepidine as new hope for children with ADHD
Kenji Hashimoto, Tsuyoshi Sasaki
Nihon Arukoru Yakubutsu Igakkai Zasshi = Japanese Journal of Alcohol Studies & Drug Dependence
|
June 4, 2008
[Progress in diagnosis of psychiatric diseases using blood samples--recent findings of brain-periphery interaction in drug abusers]
Hiroko Hagiwara, Kenji Hashimoto
Annals of General Psychiatry
|
February 12, 2010
Sigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer's disease
Tsutomu Furuse, Kenji Hashimoto
Proceedings of the National Academy of Sciences of the United States of America
|
January 14, 2021
Reply to Reeves and Dunn: Risk for autism in offspring after maternal glyphosate exposure
Kenji Hashimoto, Bruce D Hammock
Journal of Clinical Psychopharmacology
|
September 2, 2011
Effects of add-on cilostazol on cognition in patients with schizophrenia: an open-label pilot trial
Yukihiko Shirayama, Takeshi Konishi, Kenji Hashimoto
Molecular Psychiatry
|
April 7, 2022
Comments to "Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists" by Khani and Entezari-Maleki
Yaeko Hashimoto, Takuji Suzuki, Kenji Hashimoto
Page
of 87